-
Mashup Score: 1Bridging New Technology Into Clinical Practice With Mobile Apps, Electronic Patient-Reported Outcomes, and Wearables - 2 year(s) ago
With sophisticated mobile and wearable technologies available, there has been interest in leveraging these devices to help gather and analyze patient-generated health data (PGHD). This information could be used to better address health concerns, aid in treatment decision-making, and guide interventional strategies to improve outcomes. Among PGHD, electronic patient-reported outcomes, direct…
Source: ASCO Educational BookCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The Multimodal Management of Locally Advanced Rectal Cancer: Making Sense of the New Data - 2 year(s) ago
In the past 40 years, the treatment of locally advanced rectal cancer has evolved with the addition of radiotherapy or chemoradiotherapy and providing (neo)adjuvant systemic chemotherapy to major surgery. However, recent trends have focused on improving our ability to risk-stratify patients and tailoring treatment to achieve the best oncologic outcome while limiting the impact on long-term…
Source: ASCO Educational BookCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Drs. Wouter H. Zwart, Alexandra Hotca, @GekeHospers, @KarynAGoodman, & @DrGarciaAguilar discuss the W&W approach to organ preservation, total neoadjuvant treatment & how to achieve a cCR for rectal cancer in #ASCOEdBook ➡️ https://t.co/pURnGZYhwS #gicsm https://t.co/g4CQ9xNXq0
-
-
Mashup Score: 0Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy - 2 year(s) ago
The treatment scenario for patients with resectable non–small cell lung cancer has changed dramatically with the incorporation of immunotherapy. The introduction of immunotherapy into treatment algorithms has yielded improved clinical outcomes in several phase II and III trials in both adjuvant (Impower010 and PEARLS) and neoadjuvant settings (JHU/MSK, LCMC3, NEOSTAR, Columbia/MGH, NADIM, and…
Source: ASCO Educational BookCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Drs. @MARIANOPROVENCI, @VirginiaCalvo6, Atocha Romero, @DoctorJSpicer & @CruzAPhD discuss the good & the bad of #adjuvant vs #neoadjuvant therapy in #lungcancer for #ASCOEdBook: https://t.co/KWvrfjbYEU @LiquidBiopsyLab #LCSM https://t.co/hMaseuTr6X
-
-
Mashup Score: 3Leveraging Digital Technology to Reduce Cancer Care Inequities - 2 year(s) ago
The rise of digital technologies such as telehealth, mobile apps, electronic medical records, and telementoring for rural primary care providers could provide opportunities for improving equity in cancer care delivery and outcomes. Benefitting from new technologies requires access to broadband internet, appropriate devices (smartphones, computers, etc.) along with basic digital literacy skills to…
Source: ASCO Educational BookCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCO: How can we leverage digital technology to reduce #cancercare inequities? 📖 Read in #ASCOEdBook ➡️ https://t.co/4CHbe8hpb6 @trans…
-
-
Mashup Score: 8New Directions for Mantle Cell Lymphoma in 2022 - 2 year(s) ago
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International…
Source: ASCO Educational BookCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New therapies for #MCL: an overview including insights on prognostication, current management & novel agents: https://t.co/nFymcSiWrD #ASCOEdBook #lymsm #ASCO22 @DrAnitaKumar @tobyeyre82 @Dr_KatLewis @MCThompsonMD @chanyooncheah https://t.co/pDuu3JmNaa
-
-
Mashup Score: 1Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices - 2 year(s) ago
There has been a rapid uptick in the pace of oncology precision medicine advancements over the past several decades as a result of increasingly sophisticated technology and the ability to study more patients through innovative trial designs. As more precision oncology approaches are developed, the need for precision medicine trials is increasing in the community setting, where most patients with…
Source: ASCO Educational BookCategories: Hem/Oncs, Latest HeadlinesTweet-
Implementing #PrecisionMedicine Programs and #ClinicalTrials in the Community-Based Oncology: Practice: Barriers and Best Practices [May 23, 2018] @JLErsek @lorablk @mtmdphd @DrEdKim #ASCO18 Educational Book https://t.co/UJqfs6tqON https://t.co/g4gmLatTK9
-
-
Mashup Score: 8Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer - 2 year(s) ago
Triple-negative breast cancer (TNBC) is the most aggressive histologic subtype of breast cancer for which, until recently, treatment options have been limited to chemotherapy. In recent years, an improved understanding of the importance of tumor-infiltrating lymphocytes and the tumor microenvironment in TNBC has led to investigation of immune checkpoint inhibitors for treatment. There is now…
Source: ASCO Educational BookCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ASCO: Learn how to use #immunotherapy to treat #TNBC in the #ASCOEdBook 👉 https://t.co/pyZ7v4zjdR #BCSM @LoiSher @J_DixonDouglas @Loibl…
-
Learn how to use #immunotherapy to treat #TNBC in the #ASCOEdBook 👉 https://t.co/pyZ7v4zjdR #BCSM @LoiSher @J_DixonDouglas @LoiblSibylle @melindatelli https://t.co/slyyGCM3EK
-
-
Mashup Score: 6
The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Food and Drug Administration has approved sunitinib and pembrolizumab in the adjuvant setting for renal cell carcinoma and nivolumab for urothelial carcinoma based on disease-free survival benefit. The U.S. Food and Drug Administration held a joint workshop with the National Cancer…
Source: ASCO Educational BookCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Overview of the rapidly evolving role of adjuvant therapy in #RCC & urothelial cancer by Drs. @apolo_andrea, @PavlosMsaouel, @ScotNiglio, @EliasChandran, @chana_weinstock, Deborah Maskens, Gabriela Perez & Karla V. Ballman for #ASCOEdBook: https://t.co/2lh7INI56d #gucsm https://t.co/tQ8o3xZ5fc
-
-
Mashup Score: 13New Directions for Mantle Cell Lymphoma in 2022 - 2 year(s) ago
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International…
Source: ASCO Educational BookCategories: Hematologists1, Latest HeadlinesTweet-
RT @smbenlazar: New Directions for Mantle Cell Lymphoma in 2022 https://t.co/1nrYJ4km0h #lymsm #lymphoma https://t.co/44Ve8oWDCd
-
-
Mashup Score: 4New Directions for Mantle Cell Lymphoma in 2022 - 2 year(s) ago
Mantle cell lymphoma is a rare B-cell non-Hodgkin lymphoma that is clinically and biologically heterogeneous. Risk stratification at the time of diagnosis is critical. One of the most powerful prognostic indices is the Mantle Cell Lymphoma International Prognostic Index-Combined, which integrates an estimate of proliferation (Ki67 index) with the standard Mantle Cell Lymphoma International…
Source: ASCO Educational BookCategories: Hem/Oncs, Latest HeadlinesTweet-
New Directions for Mantle Cell Lymphoma in 2022 https://t.co/1nrYJ4km0h #lymsm #lymphoma https://t.co/44Ve8oWDCd
-
Learn about how electronic patient reported outcomes, mobile apps & wearable technologies are changing how we deliver oncology care ➡️ https://t.co/t04AhmFabK @hannahdzmd @tomleblancMD #ASCOEdBook #healthtech https://t.co/DX4zSzMiXE